Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

William Blair cuts Selecta Biosciences to MP

William Blair downgraded Selecta Biosciences (NASDAQ:SELB) to “market perform” after the company and partner, Swedish Orphan Biovitrum, announced top-line data from the Phase 2 COMPARE trial, comparing Selecta’s SEL-212...

October 1, 2020

Developments

Clarigent Health launches Clairity suicide risk identification app

Closely-held Clarigent Health launched Clairity, an app-based listening tool designed to provide clinical decision support to mental health professionals. Clairity uses AI to analyze speech and identify vocal...

October 1, 2020

Developments

Soleno Therapeutics updates topline data from Phase 3 Prader-Willi Syndrome trial

Soleno Therapeutics (NASDAQ:SLNO) updated topline results from its Phase 3 trial evaluating diazoxide choline controlled-release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS). The randomized, double...

September 30, 2020

Developments

Ocular Therapeutix doses first patients in Phase 2 dry eye disease trial

Ocular Therapeutix (NASDAQ:OCUL) dosed the first patients in its Phase 2 trial evaluating OTX-CSI for the treatment of dry eye disease. The trial will enroll some 105 patients who will receive either one of two...

September 29, 2020

Developments

Forte Biosciences doses first patient in Phase 2 atopic dermatitis trial

Forte Biosciences (NASDAQ:FBRX) dosed the first patient in its Phase 2 trial evaluating FB-401 for the treatment of atopic dermatitis. FB-401 is a topical mixture comprised primarily of three strains of the commensal...

September 29, 2020

Developments

Concert completes enrollment in Phase 2 schizophrenia trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its Phase 2 study evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia. The trial enrolled 325 patients already on a stable course...

September 29, 2020

Developments

Field Trip Psychedelics completes GLP synthesis of FT-104

Closely-held Field Trip Psychedelics successfully completed GLP synthesis of its psychedelic molecule, FT-104. FT-104 is a new chemical substance designed to be a commercially viable alternative to naturally derived...

September 29, 2020

Executive Moves

PharmaJet appoints Melissa Malhame as VP business development

Melissa Malhame Closely-held PharmaJet appointed Melissa Malhame as its VP of business development, where she will lead the company’s business development, sales, and marketing operations. “[Ms. Malhame’s] strategic...

September 29, 2020

Developments

Imagin Medical to host KOL webcast on Oct. 29

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will host a virtual investor event with key opinion leaders on Oct. 29 at 12:00 pm ET to highlight the potential of the company’s i/Blue...

September 29, 2020

Developments

Soricimed receives $500,000 in Government of Canada funding

Closely-held Soricimed Biopharma received $500,000 in funding from the Government of Canada to support the company’s continued research and development work. The Government of Canada provided the repayable contribution...

September 29, 2020

Developments

Zucara doses first subject in Phase 1 trial of ZT-01

Closely-held Zucara Therapeutics dosed the first subject in its Phase 1 trial of ZT-01, a once-daily somatostatin inhibitor designed to prevent insulin-induced hypoglycemia. The first, single ascending dose portion...

September 29, 2020

Developments

Kane Biotech, Animalcare to form STEM Animal Health

Kane Biotech (TSX-V:KNE) and UK-based Animalcare Group (AIM:ANCR) signed a pact to form STEM Animal Care, a company dedicated to treating biofilm-related ailments in animals. Under the accord, Animalcare will launch...

September 28, 2020

Subscribe